CTSO (CytoSorbents Corp.) Return on Sales by Gross Profit

The resilience of Cytosorbents (CTSO) is based on patent protection of blood purification systems and strict FDA control. Gross profit margins confirm this stability, where the 72.90 parameter determines the metric's magnitude. Growth is driven by high-margin sales of disposable cartridges, while the foundation of success is a staff of unique development engineers demonstrating high loyalty to the company within a niche medical segment.
Comprehensive metric breakdowns and analytics for CytoSorbents Corp. (CTSO)

Gross margin serves as a key filter during asset stress testing, determining a business's ability to generate profit after covering direct production costs. The current value of 72.90 reflects the share of revenue retained by Cytosorbents (CTSO), while the sales margin demonstrates how the high cost of innovative Purifi systems and blood purification technologies converts into the company's operational efficiency.